# Vibliome Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vibliome-therapeutics

- Industry: Biotechnology
- Headquarters: Bozeman, US
- Website: www.vibliome.com
- Total disclosed funding: $38M
- Latest round: Series A (Feb 24, 2022)
- Investors on record: 1

## About

Based in Massachusetts, US, and founded in 2017 by Gary Flynn, Vibliome Therapeutics, LLC, is a research-based organization involved in the study of small-molecule Type II Kinase inhibitors for the treatment of cancer and other diseases. In February 2022, Vibliome Therapeutics, LLC raised USD 22 million in Series A funding led by returning investor Deerfield Management. As of May 2022, the company has offices in Bozeman, Montana, and New York and is being led by Robert Goodwin as its CEO.

Vibliome develops Type II inhibitors that bind to kinase targets and keep them in an inactive state. The firm enables early profiling of its Type II discovery library against a panel of more than 300 kinase targets, as opposed to target-driven high-throughput screening approaches. This method creates a SAR database that can be utilized to build new Type II kinase inhibitors to enhance precision medicine methods for cancer and other disorders that need selective kinase targeting.

The company intends to use the May 2022 funding to complete development candidates and advance the program into clinical trials in oncology indications.

## Funding rounds

- Series A, Feb 24, 2022, $22M — Deerfield Management
- Series A, Feb 13, 2019, $16M — Deerfield Management

## Investors

- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A